Status:
COMPLETED
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
Lead Sponsor:
Watson Pharmaceuticals
Conditions:
Overactive Bladder
Urinary Incontinence
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)
Eligibility Criteria
Inclusion
- Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency
Exclusion
- Patients for whom Oxytrol(r) is contraindicated.
- Patients treated with Oxytrol(r) prior to participation in this study.
- Patients residing in long-term care facilities or nursing homes.
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2005
Estimated Enrollment :
2878 Patients enrolled
Trial Details
Trial ID
NCT00224146
Start Date
May 1 2004
End Date
May 1 2005
Last Update
November 30 2011
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Mobile, Alabama, United States
2
Tucson, Arizona, United States
3
Torrance, California, United States
4
Rocky Hill, Connecticut, United States